Intensity Therapeutics, Inc. Common stock (INTS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $10.17M
Last updated: Nov 17, 2026 at 11:04 AM ET
Intensity Therapeutics, Inc. Common stock (INTS) Competitors
The companies most similar to Intensity Therapeutics, Inc. Common stock are Marker Therapeutics (MRKR), Tempest Therapeutics (TPST) and Tscan Therapeutics (TCRX). By market cap, Intensity Therapeutics, Inc. Common stock ranks 8th of the 13 companies on this page; Plus Therapeutics (PSTV) is the largest at $26.64M.
Peer Comparison
INTS's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Intensity Therapeutics, Inc. Common stock (INTS) | $10.17M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Marker Therapeutics Inc (MRKR) | $14.51M | N/A | 14.5x | -245.5% | N/A | -51.0% | 0.00% |
| Tempest Therapeutics Inc (TPST) | $7.64M | N/A | N/A | 0.0% | -783.6% | 0.0% | 0.00% |
| Tscan Therapeutics Inc (TCRX) | $10.89M | N/A | 3.6x | 0.0% | -129.7% | -65.8% | 0.00% |
| GT Biopharma Inc (GTBP) | $7.67M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| In8bio Inc (INAB) | $8.86M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Plus Therapeutics Inc (PSTV) | $26.64M | N/A | 2.0x | -230.2% | -827.8% | -2.9% | 0.00% |
| Theriva Biologics Inc. (TOVX) | $6.61M | N/A | 21.5x | 0.0% | -52.3% | 0.0% | 0.00% |
| Tvardi Therapeutics, Inc. (TVRD) | $15.74M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Quantum BioPharma Ltd. (QNTM) | $10.35M | N/A | N/A | 0.0% | -150.1% | 0.0% | 0.00% |
| CytoMed Therapeutics Limited Ordinary Shares (GDTC) | $9.90M | N/A | 16.4x | 0.0% | -72.3% | -15.9% | 0.00% |
| Dyadic International Inc (DYAI) | $13.10M | N/A | 4.4x | -200.5% | -224.8% | -0.6% | 0.00% |
| Citius Pharmaceuticals Inc (CTXR) | $14.69M | N/A | 1.9x | 0.0% | -84.3% | 0.0% | 0.00% |
| Peer median | $10.62M | N/A | 4.4x | 0.0% | -139.9% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Intensity Therapeutics, Inc. Common stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Marker Therapeutics Inc (MRKR) | Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based... | MRKR competitors |
| Tempest Therapeutics Inc (TPST) | Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated... | TPST competitors |
| Tscan Therapeutics Inc (TCRX) | Tscan Therapeutics Inc (TCRX) is a pioneering clinical-stage biotechnology company specializing in precision oncology through its proprietary T cell receptor... | TCRX competitors |
| GT Biopharma Inc (GTBP) | GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its... | GTBP competitors |
| In8bio Inc (INAB) | IN8bio, Inc., a clinical-stage biotechnology company, is focused on developing new therapies for the treatment of cancers... | INAB competitors |
| Plus Therapeutics Inc (PSTV) | Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing... | PSTV competitors |
| Theriva Biologics Inc. (TOVX) | Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need. | TOVX competitors |
| Tvardi Therapeutics, Inc. (TVRD) | Tvardi Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company focused on developing novel oncology therapies to meet critical unmet... | TVRD competitors |
| Quantum BioPharma Ltd. (QNTM) | Quantum BioPharma Ltd. (QNTM) is an innovative biotechnology company focused on advancing transformative therapies for oncology and autoimmune diseases. | QNTM competitors |
| CytoMed Therapeutics Limited Ordinary Shares (GDTC) | CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human... | |
| Dyadic International Inc (DYAI) | Dyadic International, Inc., a biotechnology platform company, develops, produces and sells enzymes and other proteins in the United States. | DYAI competitors |
| Citius Pharmaceuticals Inc (CTXR) | Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets critical care products. | CTXR competitors |
Frequently Asked Questions About INTS
Who are Intensity Therapeutics, Inc. Common stock's main competitors?
The companies most similar to Intensity Therapeutics, Inc. Common stock include Marker Therapeutics (MRKR), Tempest Therapeutics (TPST), Tscan Therapeutics (TCRX), GT Biopharma (GTBP) and In8bio (INAB), listed from the closest match.
Who is Intensity Therapeutics, Inc. Common stock's biggest competitor?
Plus Therapeutics (PSTV) is the largest of the similar companies at $26.64M; Marker Therapeutics (MRKR) is the closest match by business profile, size, sector and industry.
How does INTS stock compare with its competitors?
INTS' net margin is 0.0% against a peer median of 0.0%.
Which of Intensity Therapeutics, Inc. Common stock's competitors pays a higher dividend?
Intensity Therapeutics, Inc. Common stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Intensity Therapeutics, Inc. Common stock bigger than its competitors?
No. Intensity Therapeutics, Inc. Common stock is 8th by market cap among the 13 companies on this page; the largest is Plus Therapeutics (PSTV) at $26.64M.
INTS pages: Overview, Earnings, Forecast, Financials, Competitors